mhurhangee/patent-ind-claim-en huggingface dataset:
A method for optimising combustion in combustion devices, the method comprising the following steps: a) providing an oxygen enriching device , wherein the oxygen enriching device comprises a chamber, the chamber comprising at least two sections , b) introducing ambient air in a laminar flow into a first section of the at least two sections , c) converting the laminar air flow from a translational movement into a rotational movement using spiral guiding surfaces disposed inside the first section of said at least two sections , d) ionising ionisable components of the ambient air by applying ionisation energy thereto in form of a pulsed direct current electric field, e) separating ionised components from non-ionised components by using the electric field, guiding the separated ionised components over a catalytic layer , and introducing the separated ionised components into a combustion chamber of a combustion device, and f) discharging the separated non-ionised components from the oxygen enriching device by passing separated non-ionized compounds from the first section into the second section . a) providing an oxygen enriching device , wherein the oxygen enriching device comprises a chamber, the chamber comprising at least two sections , b) introducing ambient air in a laminar flow into a first section of the at least two sections , c) converting the laminar air flow from a translational movement into a rotational movement using spiral guiding surfaces disposed inside the first section of said at least two sections , d) ionising ionisable components of the ambient air by applying ionisation energy thereto in form of a pulsed direct current electric field, e) separating ionised components from non-ionised components by using the electric field, guiding the separated ionised components over a catalytic layer , and introducing the separated ionised components into a combustion chamber of a combustion device, and f) discharging the separated non-ionised components from the oxygen enriching device by passing separated non-ionized compounds from the first section into the second section .
Cladribine pharmaceutical formulation for use in the treatment of multiple sclerosis wherein the Cladribine pharmaceutical formulation is to be orally administered following the sequential steps below: (i) An induction period of up to 4 months, or up to 3 months, or up to 2 months wherein the Cladribine pharmaceutical formulation is to be administered and wherein the total effective dose of Cladribine reached at the end of the induction period is about 0.7 mg/kg, wherein the total effective dose of Cladribine corresponds to a treatment of 0.35 mg/kg Cladribine per day during 5 days wherein the bioavailability of Cladribine is of about 40%, or about 1.4 mg/kg, wherein the total effective dose of Cladribine corresponds to a treatment of 0.7 mg/kg Cladribine per day during 5 days wherein the bioavailability of Cladribine is of about 40%, (ii) A Cladribine-free period of at least 8 months, wherein no Cladribine is to be administered; (iii) A maintenance period of up to 4 months, up to 3 months or up to 2 months wherein the Cladribine pharmaceutical formulation is to be administered, wherein the total effective dose of Cladribine reached at the end of the maintenance period is lower than the total effective dose of Cladribine reached at the end of the induction period (i) and is about 0.7 mg/kg, wherein said total effective dose of about 0.7 mg/kg of Cladribine corresponds to a treatment of 0.35 mg/kg Cladribine per day during 5 days wherein the bioavailability of Cladribine is of about 40%; (iv) A Cladribine-free period wherein no Cladribine is to be administered. (i) An induction period of up to 4 months, or up to 3 months, or up to 2 months wherein the Cladribine pharmaceutical formulation is to be administered and wherein the total effective dose of Cladribine reached at the end of the induction period is about 0.7 mg/kg, wherein the total effective dose of Cladribine corresponds to a treatment of 0.35 mg/kg Cladribine per day during 5 days wherein the bioavailability of Cladribine is of about 40%, or about 1.4 mg/kg, wherein the total effective dose of Cladribine corresponds to a treatment of 0.7 mg/kg Cladribine per day during 5 days wherein the bioavailability of Cladribine is of about 40%, (ii) A Cladribine-free period of at least 8 months, wherein no Cladribine is to be administered; (iii) A maintenance period of up to 4 months, up to 3 months or up to 2 months wherein the Cladribine pharmaceutical formulation is to be administered, wherein the total effective dose of Cladribine reached at the end of the maintenance period is lower than the total effective dose of Cladribine reached at the end of the induction period (i) and is about 0.7 mg/kg, wherein said total effective dose of about 0.7 mg/kg of Cladribine corresponds to a treatment of 0.35 mg/kg Cladribine per day during 5 days wherein the bioavailability of Cladribine is of about 40%; (iv) A Cladribine-free period wherein no Cladribine is to be administered.
A method for contour forming in a fiber-placement system, the method comprising: depositing a plurality of sliced layers on a stationary form to create a composite component, wherein the plurality of sliced layers includes a plurality of hoop tows, and one or more overlap splices are formed in each of the plurality of hoop tows; applying a layup heat to a plurality of target areas on the plurality of sliced layers during the depositing, wherein the plurality of target areas is spatially arranged to permit a slippage in the plurality of overlap splices when the composite component is draped on a curved tool; draping the composite component on the curved tool with the plurality of hoop tows oriented perpendicular to an axis of curvature of the curved tool; and applying a curing heat to the composite component after the composite component has been bent into a contoured shape by the curved tool, wherein the curing heat inhibits a further slippage in the plurality of overlap splices; wherein each of the plurality of overlap splices includes a non-heated area in which a first segment is overlaid with a second segment, and the non-heated area is outside of the plurality of target areas to permit the slippage. depositing a plurality of sliced layers on a stationary form to create a composite component, wherein the plurality of sliced layers includes a plurality of hoop tows, and one or more overlap splices are formed in each of the plurality of hoop tows; applying a layup heat to a plurality of target areas on the plurality of sliced layers during the depositing, wherein the plurality of target areas is spatially arranged to permit a slippage in the plurality of overlap splices when the composite component is draped on a curved tool; draping the composite component on the curved tool with the plurality of hoop tows oriented perpendicular to an axis of curvature of the curved tool; and applying a curing heat to the composite component after the composite component has been bent into a contoured shape by the curved tool, wherein the curing heat inhibits a further slippage in the plurality of overlap splices; wherein each of the plurality of overlap splices includes a non-heated area in which a first segment is overlaid with a second segment, and the non-heated area is outside of the plurality of target areas to permit the slippage.
A method for dynamically establishing file system compatibility and accessing data in real time independently of the file system, comprising: - granting access to the file system of a passive data store for an active terminal, and a modeling device (M) communicatively interposed between the passive data store and the active terminal; - receiving an access request from the active terminal by the modeling device (M), the access request specifying access data and access operations to the passive data store; - a recognition of the file system of the passive data carrier by the modeling device (M); - selecting stored access rules suitable to perform the access request according to the recognized file system of the passive data storage; - applying by the modeling device (M) the selected access rules to access data specified by the access request, the access rules mapping the access request as generated by the file system of the active terminal to the file system of the passive data store; and - performing the access operations according to the access request. - granting access to the file system of a passive data store for an active terminal, and a modeling device (M) communicatively interposed between the passive data store and the active terminal; - receiving an access request from the active terminal by the modeling device (M), the access request specifying access data and access operations to the passive data store; - a recognition of the file system of the passive data carrier by the modeling device (M); - selecting stored access rules suitable to perform the access request according to the recognized file system of the passive data storage; - applying by the modeling device (M) the selected access rules to access data specified by the access request, the access rules mapping the access request as generated by the file system of the active terminal to the file system of the passive data store; and - performing the access operations according to the access request.
Body support assembly having a top surface for supporting a human body and a spaced away bottom surface defining a cushion volume and defining side walls, wherein the air permeability of the top surface is higher than the air permeability of the bottom surface and higher than the air permeability of the side walls, wherein the cushion volume comprises, an upper cushion zone nearest to the top surface and a lower cushion zone and separated by a separation sheet , wherein the upper cushion zone and the lower cushion zone comprise of a compressible material which is permeable for air in all directions, a first flow path for ambient air comprising a single or separate air inlet opening at the bottom surface of the support assembly, air displacement means, a first heat exchanger and a single or separate air outlet opening at the bottom surface of the support assembly, a second flow path for air comprising an air inlet , air displacement means, a second heat exchanger , a flow path through the compressible material of the lower cushion zone , through openings in the separation sheet and through the compressible material of the upper cushion zone and multiple air outlets in the top surface , and wherein the first heat exchanger and the second heat exchanger and a Peltier plate , are part of a Peltier effect unit , where the first heat exchanger has fins connected to one side of the Peltier plate and the second heat exchanger has fins connected to the opposite side of the Peltier plate , where the Peltier effect unit is being positioned within the cushion volume, which unit is configured to cool the air in the first flow path and heat the air in the second flow path in one operating modus or to heat the air in the first flow path and cool the air in the second flow path in a second operating modus.
A compound of Formula (I): wherein: R 1 is H, halo, C 1-4 alkyl, or CF 3 ; R 2 is -CF 3 , or C 1-4 alkyl unsubstituted or substituted with halo or -CF 3 ; A is a 5-membered heteroaryl ring; Y is absent or is C 1-4 alkylene; where Y is absent: R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C 1-4 alkyl; and where Y is C 1-4 alkylene: R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C 1-4 alkyl; or R 3 and Y taken together with the nitrogen to which R 3 is attached form a monocyclic heterocycloalkyl ring, and R 4 is H or C 1-4 alkyl; or a pharmaceutically acceptable salt thereof. R 1 is H, halo, C 1-4 alkyl, or CF 3 ; R 2 is -CF 3 , or C 1-4 alkyl unsubstituted or substituted with halo or -CF 3 ; A is a 5-membered heteroaryl ring; Y is absent or is C 1-4 alkylene; where Y is absent: R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C 1-4 alkyl; and where Y is C 1-4 alkylene: R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C 1-4 alkyl; or R 3 and Y taken together with the nitrogen to which R 3 is attached form a monocyclic heterocycloalkyl ring, and R 4 is H or C 1-4 alkyl; or a pharmaceutically acceptable salt thereof. R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C 1-4 alkyl; and where Y is C 1-4 alkylene: R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C 1-4 alkyl; or R 3 and Y taken together with the nitrogen to which R 3 is attached form a monocyclic heterocycloalkyl ring, and R 4 is H or C 1-4 alkyl; or a pharmaceutically acceptable salt thereof. R 3 and R 4 taken together with the nitrogen to which they are attached form a monocyclic heterocycloalkyl ring, unsubstituted or substituted with C 1-4 alkyl; or R 3 and Y taken together with the nitrogen to which R 3 is attached form a monocyclic heterocycloalkyl ring, and R 4 is H or C 1-4 alkyl;
An isolated peptide selected from the group consisting of the sequences VAFIGKYGQQLNFGVA, IGKYGQQLNFGVARVF, FFLNQKKAKMVLHKTA, GGVKFTVVNNHFPQYV, KFTVVNNHFPQYVSNP, WIADTCKASVLKLAEA, RVLKDNMDVNFMKKVL, KDNMDVNFMKKVLRQR, MDVNFMKKVLRQRYGT, NFMKKVLRQRYGTMTA, LRQRYGTMTAEEWMTQ, RYGTMTAEEWMTQKIT, AEEWMTQKITEIKAAF, AKSGFSPAARTFLQQF, GFSPAARTFLQQFGIN.
Cather system , with a catheter that has a flexible catheter body that forms at least two cavities (90, 100/110) along its longitudinal extension, wherein the catheter can be placed circularly around and permanently attached to a structure to be reconstructed and is characterized in that the catheter body comprises at least two successively arranged sections with sluices arranged between the sections that seal off the cavities (90, 100/110) section by section, wherein - the length of the individual sections of the catheter can be changed, - one of the cavities is communicatively implemented with at least one opening in each section that penetrates the catheter walling and that serves to attach the catheter to the tissue, - the other cavity (100/110) is designed for the insertion of at least one element (40/50) that changes the length of at least one of the sections , and - wherein one cavity is designed to apply a vacuum that acts on the openings and/or the openings are designed to emit an adhesive material that fixes the catheter to the tissue and with a removably attached catheter carrier that has cavities which, in the attached state, communicate with the cavities (90 100/110) of the catheter , and are designed for the moveable insertion of the element (40/50) that changes the length of the catheter sections . - the length of the individual sections of the catheter can be changed, - one of the cavities is communicatively implemented with at least one opening in each section that penetrates the catheter walling and that serves to attach the catheter to the tissue, - the other cavity (100/110) is designed for the insertion of at least one element (40/50) that changes the length of at least one of the sections , and - wherein one cavity is designed to apply a vacuum that acts on the openings and/or the openings are designed to emit an adhesive material that fixes the catheter to the tissue
An additive injection apparatus for a laundry treating machine, comprising: a main body disposed on a path along which a solvent flows and comprising an inlet and an outlet for receiving and discharging the solvent, respectively; an additive container disposed underneath the main body, for holding an additive; a nozzle having a communicating hole for communicating between the main body and the additive container ; and a floater disposed in the main body , for rising and falling to open and close the communicating hole , wherein the floater is configured to be raised by the flow of the solvent, characterized in that the floater is configured to be raised by the flow of the solvent from the inlet to the outlet , allowing the communication hole to be opened and the solvent with the additive dissolved to be supplied to the main body through the communicating hole mainly by a diffusion action due to a concentration gradient between the main body and the additive container , wherein the center point of the inlet for receiving the solvent is located at a horizontal level below the center of floater , and wherein the floater has a specific gravity larger than the solvent. a main body disposed on a path along which a solvent flows and comprising an inlet and an outlet for receiving and discharging the solvent, respectively; an additive container disposed underneath the main body, for holding an additive; a nozzle having a communicating hole for communicating between the main body and the additive container ; and a floater disposed in the main body , for rising and falling to open and close the communicating hole , wherein the floater is configured to be raised by the flow of the solvent, characterized in that the floater is configured to be raised by the flow of the solvent from the inlet to the outlet , allowing the communication hole to be opened and the solvent with the additive dissolved to be supplied to the main body through the communicating hole mainly by a diffusion action due to a concentration gradient between the main body and the additive container , wherein the center point of the inlet for receiving the solvent is located at a horizontal level below the center of floater , and wherein the floater has a specific gravity larger than the solvent.
A method for the production of powdered lithium oxide from lithium carbonate and elemental carbon or a carbon source forming elemental carbon under the reaction conditions in the temperature range of 720 to 1200°C, characterized in that the reaction takes place under substantial exclusion of oxygen and the reaction is carried out in containers whose product-contacting surfaces are corrosion resistant to the reactants and products.
A washing machine comprising a body ; a loading port which is provided on the body ; a drum which is disposed in the body and wherein the laundry is loaded via the loading port ; a tub in which the drum is disposed; a pipe which provides the delivery of the water to the tub during the washing cycle; a lifter which is disposed in the drum , which tumbles the laundry and which has at least one nozzle for delivering the water into the drum ; a magnet which creates a magnetic field during the rotation of the drum ; a sensor which is disposed on the tub and which is configured to detect the position of the lifter with respect to the tub with the magnetic effect of the magnet ; and a control unit which is configured to stop the drum when the lifter is at the topmost position of the tub according to the data received from the sensor , the lifter having a second piece which is configured to be detachably attached to the drum and which has at least one opening for allowing the passage of water into the drum , a first piece which is configured to be detachably attached to the second piece and the magnet being disposed in the second piece characterized by the lifter having a housing on the second piece being configured to position the magnet and the housing at one side of the opening , having a rear wall and two side walls as an elevation from the surface of the second piece whereon one claw for connecting the second piece to the drum is provided.
A method for predicting responsiveness to the treatment of cancer with a compound inhibiting p300, comprising using a biological sample derived from a cancer patient, detecting the presence or absence of an inactivating mutation in CBP contained in the biological sample, and determining the patient with the detected inactivating mutation in CBP as responsive to the treatment of cancer with the compound inhibiting p300, wherein the inactivating mutation is a homozygous CBP deletion, a CBP nonsense mutation, or one of the mutations Asn83Thr, Ser893Leu, Arg1446Cys, Trp1472Cys, Asn2175Ser, Glu1835Stop, Asn2111Ser, Leu551Ile, Gly1411Glu, or Ala2044Gly.
An apparatus for treating an eye having a cornea, the apparatus comprising: a cornea profiling system to measure a profile of a posterior surface of the cornea; a laser to generate a laser beam; and a processor comprising a tangible medium coupled to the laser and configured to receive data from the cornea profiling system, the tangible medium embodying instructions to cause the processor to determine an incision profile based on the posterior surface of the cornea; and characterised in that the processor embodies instructions of a computer program to determine a first beam pulse profile to incise a donor cornea based on a posterior surface profile of the donor cornea and a second beam pulse profile to incise the recipient cornea based on the posterior surface profile of the recipient cornea, and wherein the first beam pulse profile provides a first thickness of a graft tissue to be excised from the donor cornea and the second beam pulse profile provides a second thickness of a flap of tissue to be removed from the recipient cornea to form a bed receiving the graft tissue; and wherein the first thickness is substantially similar to the second thickness in order to inhibit resection of donor lamella of the graft and resection of the recipient lamella of a bed of the recipient cornea.